-
Posted by
Two Blokes May 22, 2025 -
Filed in
Stock
-
5 views
I initiate coverage of Tempus AI, Inc. with a Buy rating, driven by its unique data assets and AI-powered oncology solutions. The company posted strong revenue growth and margin expansion, though profitability and high debt remain concerns as it integrates recent acquisitions. Tempus AI's vast clinical and molecular data, validated at major conferences, positions it as a key partner for leading pharma and healthcare companies.
